Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Efficacy of HCV treatment varies by HCV genotype and fibrosis stage
  • Some newer DAAs have activity against multiple or all genotypes
    • Ledipasvir/Sofosbuvir
    • All 3 phase III ION trials demonstrated high SVR rates with  ledipasvir/sofosbuvir with or without ribavirin when administrated for 8, 12, or 24 weeks in patients with genotype 1 HCV infection
      Sofosbuvir/Velpatasvir
        Sofosbuvir/Velpatasvir/Voxilaprevir
          Elbasvir/Grazoprevir
            Glecaprevir/Pibrentasvir
              Direct-Acting Antivirals in Cirrhotic Patients
                Ledipasvir/Sofosbuvir
                  Sofosbuvir/Velpatasvir
                    Sofosbuvir/Velpatasvir/Voxilaprevir
                      Elbasvir/Grazoprevir
                        Glecaprevir/Pibrentasvir

                      Action required

                      Keywords: Hepatitis C-Treatment

                      ©2020 Clinical Care Options, LLC. All Rights Reserved.

                      The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.